Metastatic latency, a veiled threat

Kangsan Kim, Mauricio Marquez-Palencia, Srinivas Malladi

Research output: Contribution to journalShort survey

1 Citation (Scopus)

Abstract

Metastatic relapse is observed in cancer patients with no clinical evidence of disease for months to decades after initial diagnosis and treatment. Disseminated cancer cells that are capable of entering reversible cell cycle arrest are believed to be responsible for these late metastatic relapses. Dynamic interactions between the latent disseminated tumor cells and their surrounding microenvironment aid cancer cell survival and facilitate escape from immune surveillance. Here, we highlight findings from preclinical models that provide a conceptual framework to define and target the latent metastatic phase of tumor progression. The hope is by identifying patients harboring latent metastatic cells and providing therapeutic options to eliminate metastatic seeds prior to their emergence will result in long lasting cures.

Original languageEnglish (US)
Article number1836
JournalFrontiers in immunology
Volume10
Issue numberAUG
DOIs
StatePublished - Jan 1 2019

Fingerprint

Neoplasms
Recurrence
Tumor Microenvironment
Cell Cycle Checkpoints
Cell Survival
Seeds
Therapeutics

Keywords

  • Dormancy
  • Immune-surveillance
  • Latency
  • Metastasis
  • Microenvironment
  • Minimal residual disease

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Metastatic latency, a veiled threat. / Kim, Kangsan; Marquez-Palencia, Mauricio; Malladi, Srinivas.

In: Frontiers in immunology, Vol. 10, No. AUG, 1836, 01.01.2019.

Research output: Contribution to journalShort survey

Kim, Kangsan ; Marquez-Palencia, Mauricio ; Malladi, Srinivas. / Metastatic latency, a veiled threat. In: Frontiers in immunology. 2019 ; Vol. 10, No. AUG.
@article{7dd48d0135c24927bf5aa592782dccaa,
title = "Metastatic latency, a veiled threat",
abstract = "Metastatic relapse is observed in cancer patients with no clinical evidence of disease for months to decades after initial diagnosis and treatment. Disseminated cancer cells that are capable of entering reversible cell cycle arrest are believed to be responsible for these late metastatic relapses. Dynamic interactions between the latent disseminated tumor cells and their surrounding microenvironment aid cancer cell survival and facilitate escape from immune surveillance. Here, we highlight findings from preclinical models that provide a conceptual framework to define and target the latent metastatic phase of tumor progression. The hope is by identifying patients harboring latent metastatic cells and providing therapeutic options to eliminate metastatic seeds prior to their emergence will result in long lasting cures.",
keywords = "Dormancy, Immune-surveillance, Latency, Metastasis, Microenvironment, Minimal residual disease",
author = "Kangsan Kim and Mauricio Marquez-Palencia and Srinivas Malladi",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fimmu.2019.01836",
language = "English (US)",
volume = "10",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - Metastatic latency, a veiled threat

AU - Kim, Kangsan

AU - Marquez-Palencia, Mauricio

AU - Malladi, Srinivas

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Metastatic relapse is observed in cancer patients with no clinical evidence of disease for months to decades after initial diagnosis and treatment. Disseminated cancer cells that are capable of entering reversible cell cycle arrest are believed to be responsible for these late metastatic relapses. Dynamic interactions between the latent disseminated tumor cells and their surrounding microenvironment aid cancer cell survival and facilitate escape from immune surveillance. Here, we highlight findings from preclinical models that provide a conceptual framework to define and target the latent metastatic phase of tumor progression. The hope is by identifying patients harboring latent metastatic cells and providing therapeutic options to eliminate metastatic seeds prior to their emergence will result in long lasting cures.

AB - Metastatic relapse is observed in cancer patients with no clinical evidence of disease for months to decades after initial diagnosis and treatment. Disseminated cancer cells that are capable of entering reversible cell cycle arrest are believed to be responsible for these late metastatic relapses. Dynamic interactions between the latent disseminated tumor cells and their surrounding microenvironment aid cancer cell survival and facilitate escape from immune surveillance. Here, we highlight findings from preclinical models that provide a conceptual framework to define and target the latent metastatic phase of tumor progression. The hope is by identifying patients harboring latent metastatic cells and providing therapeutic options to eliminate metastatic seeds prior to their emergence will result in long lasting cures.

KW - Dormancy

KW - Immune-surveillance

KW - Latency

KW - Metastasis

KW - Microenvironment

KW - Minimal residual disease

UR - http://www.scopus.com/inward/record.url?scp=85071983146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071983146&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2019.01836

DO - 10.3389/fimmu.2019.01836

M3 - Short survey

C2 - 31447846

AN - SCOPUS:85071983146

VL - 10

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - AUG

M1 - 1836

ER -